1177 — Sino Biopharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Sino Biopharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	23,647	26,861	26,026	26,199	28,866
Cost of Revenue
Gross Profit	18,465	21,529	21,539	21,210	23,530
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	18,308	21,611	20,229	19,769	23,675
Operating Profit	5,340	5,251	5,797	6,431	5,191
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	5,013	18,573	5,215	5,410	5,277
Provision for Income Taxes
Net Income After Taxes	4,341	16,615	4,518	4,613	4,785
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	2,771	14,608	2,544	2,332	3,500
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	2,771	14,126	2,311	2,332	3,500
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.147	0.762	0.097	0.101	0.157
Dividends per Share